在标准护理系统治疗后,高级固体瘤患者的血损伤相关分子模式的变化
Vicente Valentí1, Laia Capdevila1, Isabel Ruiz2
1Medical Oncology, Hospital Santa Tecla, Tarragona, Spain.
Cancer investigation
|November 17, 2023
概括
这项研究发现,癌症治疗后S100A8水平的下降与更好的患者结局相关,而HMGB1水平与治疗反应或生存没有显著的关联. 这些发现表明S100A8可能作为炎症标记物.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 生物标志物发现发现
背景情况:
- 免疫性细胞死亡 (ICD) 从瘤细胞中释放与损伤相关的分子模式 (DAMPs).
- 在治疗前和治疗后评估血DAMP (HMGB1,S100A8) 可以识别晚期实体瘤中的ICD信号.
研究的目的:
- 为了研究血HMGB1和S100A8的变异,作为免疫细胞死亡 (ICD) 的潜在指标,在高级固体瘤的标准护理系统治疗后.
- 探索这些DAMP变化与治疗反应,无进展生存期 (PFS) 和整体生存期 (OS) 之间的相关性.
主要方法:
- 测量HMGB1和S100A8的血度是在系统治疗前三个月和三个月后,在52名患有晚期固体瘤的患者中测量.
- 使用RECIST标准评估瘤反应.
- 与DAMP度变化相关的无进展生存 (PFS) 和总生存 (OS) 被分析.
主要成果:
- 治疗后观察到血中位数S100A8度显著下降,特别是在瘤反应 (p=0.002) 的患者中.
- 在治疗前和治疗后没有发现HMGB1水平的显著差异,也没有与瘤反应相关.
- 治疗后S100A8的下降显着与更长的PFS (12 vs. 4.7个月; p<0.001) 和OS (16.7 vs. 9.0个月; p<0.001) 相关.
结论:
- 该研究没有观察到免疫细胞死亡 (ICD) 的明确信号.
- 似乎S100A8作为炎症标志物起作用,其治疗后的下降与改善的患者结果有关.
- 治疗后降低的S100A8水平预测了晚期固体瘤患者的显著更长的PFS和OS.
相关概念视频
01:27Tumor Immunotherapy
530
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
530
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K